Safety and efficacy of esmolol (ASL-8052: An ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias
- 1 February 1984
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 3 (2) , 394-399
- https://doi.org/10.1016/s0735-1097(84)80025-x
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Pharmacology of ASL-8052, a Novel β-Adrenergic Receptor Antagonist with an Ultrashort Duration of ActionJournal of Cardiovascular Pharmacology, 1983
- Esmolol: A Pharmacokinetic Profile of a New Cardioselective β-Blocking AgentJournal of Pharmaceutical Sciences, 1983
- Ultra-short acting beta-blockers: A proposal for the treatment of the critically ill patientLife Sciences, 1982
- The electrophysiologic effects of intravenous propranolol in the Wolff-Parkinson-White syndromeAmerican Heart Journal, 1979
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applicationsAmerican Heart Journal, 1979
- Effects of propranolol on anomalous pathway refractoriness and circus movement tachycardias in patients with preexcitationThe American Journal of Cardiology, 1978
- Present state of alpha and beta adrenergic drugs III. Beta blocking agentsAmerican Heart Journal, 1977
- Perspectives in adrenergic beta‐receptor blockadeClinical Pharmacology & Therapeutics, 1969